Skip to content

Exploration of a standardized dosing regimen of tranexamic acid during the perioperative period of high tibial osteotomy

Exploration of a standardized dosing regimen of tranexamic acid during the perioperative period of high tibial osteotomy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113834
Enrollment
Unknown
Registered
2025-12-03
Start date
2025-03-26
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reduced postoperative blood loss

Interventions

Group A:Intraoperative intravenous tranexamic acid
Group B:Intraoperative local injection of tranexamic acid
Group C:Intraoperative intravenous and local combined administration of tranexamic acid

Sponsors

Tianjin Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with symptomatic medial compartment knee osteoarthritis accompanied by varus deformity requiring correction via high tibial osteotomy. 2. Normal joint range of motion 3. ASA physical status classification I–III 4. Osteotomy spread angle between 8–12° 5. Patients who signed informed consent prior to the study 6. Kellgren-Lawrence classification grade 2–3

Exclusion criteria

Exclusion criteria: 1. Patients allergic to tranexamic acid 2. Patients with a history of coagulation disorders 3. History of venous thromboembolism 4. Patients with preoperative hemoglobin <100g/L; those still on anticoagulant therapy preoperatively 5. Severe cardiovascular or cerebrovascular disease 6. Patients who have used antiplatelet agents within 7 days prior to surgery 7. Patients who have used thrombolytic agents within 7 days prior to surgery 8. Severe hepatic or renal dysfunction 9. Use of medications with blood-thinning or blood-concentrating effects during the perioperative period 10. Patients who have used hemostatic agents or hemostatic plasma products within 7 days prior to surgery, or who experienced major hemorrhage within one month prior to surgery

Design outcomes

Primary

MeasureTime frame
Decreased hemoglobin values;specific volume of red blood cells;Size of hematoma on ultrasound;Perioperative blood loss;

Secondary

MeasureTime frame
Postoperative sleep quality score;Postoperative VAS score;Postoperative Anxiety Scale Score;C-reactive protein count;Quality of Life Score at Two Months Post-Surgery;

Countries

China

Contacts

Public ContactLina Zhao

Department of Anesthesiology, Tianjin Hospital

zhaolina1984@126.com+86 151 2204 6629

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026